Since the initial discovery of the NPM–ALK fusion protein in ALCL patients [13,14], ALK fusion proteins have been identified in various other tumors, such as inflammatory myofibroblastic tumors (IMTs) [19] and non-small-cell lung cancer (NSCLC) [20,21]. Here, ALK is linked to inflammatory myofibroblastic tumor.